{"product_id":"revb-vrio-analysis","title":"Revelation Biosciences, Inc. (REVB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Revelation Biosciences, Inc. (REVB)'s market dominance by diving into this essential VRIO Analysis. We rigorously test whether its core assets are truly Valuable, Rare, Inimitable, and Organized enough to secure a lasting competitive advantage. Discover the distilled summary of its strengths and weaknesses - the key to its future performance - by reading on below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Proprietary Gemini Formulation (PHAD®)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset of Revelation Biosciences, Inc., the Proprietary Gemini Formulation (PHAD®), and trying to figure out if it’s a durable competitive edge. Honestly, in the biotech space, the science is the moat, provided it works in humans and you can protect it.\u003c\/p\u003e\n\n\u003ch3\u003eProprietary Gemini Formulation (PHAD®)\u003c\/h3\u003e\n\n\u003cp\u003eThe PHAD® molecule, which is phosphorylated hexaacyl disaccharide, is what Gemini is built on. It’s designed to reprogram the innate immune system to manage inflammation, which is a huge target area. The recent data from the PRIME Phase 1b study in Chronic Kidney Disease (CKD) patients shows this isn't just theory; the primary safety endpoint was met, and they saw significant biomarker changes.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the clinical validation as of late 2025:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePRIME study enrolled \u003cstrong\u003e40 patients\u003c\/strong\u003e across \u003cstrong\u003e5 cohorts\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGemini significantly reduced inflammatory markers like IL-1β (\u003cstrong\u003ep\u0026lt;0.01\u003c\/strong\u003e) versus placebo in patients with high background inflammation.\u003c\/li\u003e\n\u003cli\u003eThe company is on track for an End-of-Phase 1 meeting with the FDA for Gemini as an Acute Kidney Injury (AKI) treatment, following submission acceptance on November 20, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis clinical traction definitely translates to tangible value right now.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status (as of Q3 2025)\u003c\/th\u003e\n\u003cth\u003eSource of Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12.7 million\u003c\/strong\u003e (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eFunds operations through \u003cstrong\u003eQ3 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNine-Month Net Loss\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.4 million\u003c\/strong\u003e (Jan-Sep 2025)\u003c\/td\u003e\n\u003ctd\u003eImproved efficiency vs. $13.3 million loss in prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Activity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.6 million\u003c\/strong\u003e from warrant inducement (Sep 2025)\u003c\/td\u003e\n\u003ctd\u003eProvided capital to advance development path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Clinical Endpoint\u003c\/td\u003e\n\u003ctd\u003eSafety\/Tolerability met in PRIME Study\u003c\/td\u003e\n\u003ctd\u003eDe-risks the asset for later-stage trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity and Imitability\u003c\/h3\u003e\n\n\u003cp\u003eThe Rarity component hinges on the molecule itself. Revelation Biosciences holds an exclusive worldwide license from Vanderbilt University for the development of PHAD®. This specific molecule and its formulation are unique to them; you can’t just swap it out for something else and get the same mechanism of action. That exclusivity is key.\u003c\/p\u003e\n\n\u003cp\u003eImitability is where the moat gets thicker, assuming the science holds up. Because the value is tied to a specific, proprietary chemical structure and a unique delivery method (intravenously administered), direct imitation is hard. It requires replicating complex chemistry and navigating the intellectual property landscape. Revelation plans to prosecute additional patent applications, which suggests they are actively building layers around this core asset. If you don't have the license or the underlying know-how, you’re stuck trying to invent around a known target, which is time-consuming and expensive.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization and Competitive Advantage\u003c\/h3\u003e\n\n\u003cp\u003eOrganization is about how well the company is structured to exploit this asset. Right now, the entire corporate narrative and resource allocation are centered on Gemini. CEO James Rolke’s stated near-term focus is on the FDA meeting and initiating a later-stage clinical study during \u003cstrong\u003e2026\u003c\/strong\u003e for AKI. This alignment - from R\u0026amp;D to finance - shows focus. The company raised capital in May 2025 and September 2025 to ensure they have the runway to execute this plan.\u003c\/p\u003e\n\n\u003cp\u003eThe Competitive Advantage here is \u003cstrong\u003eSustained\u003c\/strong\u003e, but it’s conditional. If Gemini successfully navigates the FDA process and proves efficacy in larger trials for AKI or CKD, the combination of unique, licensed IP and a company wholly organized around its advancement creates a strong, defensible position. If onboarding takes 14+ days, churn risk rises, but for a drug candidate, clinical failure is the real risk to the advantage. Right now, the advantage is sustained pending successful progression through Phase 2\/3 trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus areas include AKI, CKD, and prevention for post-surgical infection (PSI).\u003c\/li\u003e\n\u003cli\u003eOrganizational goal is initiating a later-stage study in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe exclusive license is the foundation of the defensible asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Trained Immunity Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This underlying scientific concept - harnessing trained immunity - allows for multiple indications from one mechanism, which is capital-efficient if proven.\u003c\/p\u003e\n\u003cp\u003eThe Gemini platform, based on phosphorylated hexaacyl disaccharide (PHAD), is a \u003cstrong\u003eTLR4 agonist\u003c\/strong\u003e designed to stimulate the innate immune response. The platform supports multiple product candidates:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGemini-SSI for surgical site infection (SSI) prevention.\u003c\/li\u003e\n\u003cli\u003eGemini-AKI for acute kidney injury (AKI) prevention.\u003c\/li\u003e\n\u003cli\u003eGemini-CKD for chronic kidney disease (CKD) treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePhase 1b PRIME study in CKD patients met its primary safety endpoint and demonstrated statistically significant pharmacodynamic activity, including \u003cstrong\u003eupregulation of IL-10\u003c\/strong\u003e. Effects remained significant through \u003cstrong\u003e7 days\u003c\/strong\u003e after a single dose.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other firms explore trained immunity, but Revelation’s specific application via Gemini is distinct.\u003c\/p\u003e\n\u003cp\u003eThe company has a lean operational model with \u003cstrong\u003e9\u003c\/strong\u003e full-time employees as of late 2025. The company was founded in \u003cstrong\u003e2019\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors can pursue similar pathways, but the lead time gained from their current clinical data is valuable.\u003c\/p\u003e\n\u003cp\u003eThe Phase 1b PRIME study enrolled \u003cstrong\u003e40 patients\u003c\/strong\u003e across \u003cstrong\u003e3 U.S.-based clinics\u003c\/strong\u003e in \u003cstrong\u003e5 cohorts\u003c\/strong\u003e testing dose levels. The company submitted its end-of-phase 1 package to the FDA for AKI.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram Indication\u003c\/td\u003e\n\u003ctd\u003eStatus\/Phase\u003c\/td\u003e\n\u003ctd\u003ePatient Enrollment (PRIME CKD)\u003c\/td\u003e\n\u003ctd\u003eKey Pharmacodynamic Finding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCKD (GEM-CKD)\u003c\/td\u003e\n\u003ctd\u003ePhase 1b (PRIME Study)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eUpregulation of \u003cstrong\u003eIL-10\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAKI (GEM-AKI)\u003c\/td\u003e\n\u003ctd\u003ePre-Phase 2 (End-of-Phase 1 meeting submitted to FDA)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Phase 1 met safety endpoint)\u003c\/td\u003e\n\u003ctd\u003eEffects lasted up to \u003cstrong\u003e7 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Site Infection (Gemini-SSI)\u003c\/td\u003e\n\u003ctd\u003ePreclinical\/Early Development\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eProprietary formulation of \u003cstrong\u003ePHAD\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere Burns\u003c\/td\u003e\n\u003ctd\u003ePreclinical\/Early Development\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTLR4 agonist\u003c\/strong\u003e mechanism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong, as evidenced by their ability to pivot Gemini into CKD, AKI, and burn indications.\u003c\/p\u003e\n\u003cp\u003eFinancial standing as of late 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents: \u003cstrong\u003e$12.7 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eProjected funding runway through \u003cstrong\u003eQ3 2026\u003c\/strong\u003e based on current operating plans.\u003c\/li\u003e\n\u003cli\u003eNet cash used for operating activities for the nine months ended September 30, 2025: \u003cstrong\u003e$6.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended September 30, 2025: \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization: Approximately \u003cstrong\u003e$6.28M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a valuable platform, but the advantage erodes if competitors validate similar approaches quickly.\u003c\/p\u003e\n\u003cp\u003eThe 52-week stock price range was between a low of \u003cstrong\u003e$0.8301\u003c\/strong\u003e and a high of \u003cstrong\u003e$60.48\u003c\/strong\u003e. The Price-Earnings ratio (TTM) was reported as \u003cstrong\u003e-0.04\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Gemini CKD Clinical Data (PRIME Study)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Groundbreaking top-line results from the PRIME Phase 1b study in Chronic Kidney Disease (CKD) patients provide crucial human proof-of-concept data.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Phase\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eStage 3 and 4 CKD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients Enrolled\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNumber of Cohorts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Levels\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtension Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint Result\u003c\/td\u003e\n\u003ctd\u003eMet (Safety and Tolerability)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflammatory Marker Reduction (IL-1β)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ep\u0026lt;0.01\u003c\/strong\u003e (in high background activity subgroup)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflammatory Marker Reduction (IL-1RA)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ep\u0026lt;0.001\u003c\/strong\u003e (in high background activity subgroup)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuration of Effect Measured\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e168 hours\u003c\/strong\u003e post-dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Positive, replicated human data in a novel mechanism is rare and de-risks the asset significantly.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDemonstrated correction of immunoparalysis typical to chronic disease.\u003c\/li\u003e\n\u003cli\u003eSignificant reduction in inflammatory activity in patients with high background PBMC activity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors cannot imitate past trial results; they must generate their own.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Excellent. They successfully completed dosing and announced positive data in September 2025, showing execution capability.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eData Announcement Date: September \u003cstrong\u003e9\u003c\/strong\u003e, 2025.\u003c\/li\u003e\n\u003cli\u003eFinancing: Received gross proceeds of \u003cstrong\u003e$9.6 million\u003c\/strong\u003e from warrant inducement in September 2025.\u003c\/li\u003e\n\u003cli\u003eCash Position: Cash \u0026amp; Cash Equivalents of \u003cstrong\u003e$12.71 million\u003c\/strong\u003e (as of latest reported).\u003c\/li\u003e\n\u003cli\u003eNet Loss (9 months ended Sep 30, 2025): \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This data is a sunk cost for them and a massive hurdle for any new entrant in this specific indication.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eData provides human proof-of-concept for Gemini's mechanism of action.\u003c\/li\u003e\n\u003cli\u003eFDA End-of-Phase 1 meeting package accepted for scheduling later in 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Gemini AKI Regulatory Pathway Progress\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSuccessful submission and acceptance of the end-of-Phase 1 meeting package to the FDA for Acute Kidney Injury (AKI) treatment by \u003cstrong\u003eNovember 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company plans to conduct a later-stage clinical study during \u003cstrong\u003e2026\u003c\/strong\u003e to evaluate Gemini's effectiveness in treating AKI.\u003c\/li\u003e\n\u003cli\u003eThe Phase 1b PRIME clinical study enrolled \u003cstrong\u003e40 patients\u003c\/strong\u003e across \u003cstrong\u003ethree U.S.-based clinics\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAchieving this milestone shows effective navigation of the regulatory process for the lead asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRegulatory processes are standardized, but the specific package quality and FDA acceptance are company-specific achievements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company is on track to hold the FDA meeting later in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, Revelation had \u003cstrong\u003e$12.7 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/li\u003e\n\u003cli\u003eNet cash used for operating activities for the nine months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, was \u003cstrong\u003e$6.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company maintained a current ratio of \u003cstrong\u003e6.92\u003c\/strong\u003e as of \u003cstrong\u003eNovember 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpeeds up the timeline toward a potential Phase 2\/3 start in \u003cstrong\u003e2026\u003c\/strong\u003e, but the FDA path is public knowledge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnd-of-Phase 1 package accepted by FDA on \u003cstrong\u003eNovember 20, 2025\u003c\/strong\u003e; Next study planned for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSuccessful navigation of a key regulatory step for the lead asset.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eSpecific package quality is company-specific, but processes are standardized.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eGood\u003c\/td\u003e\n\u003ctd\u003eOn track for meeting in \u003cstrong\u003e2025\u003c\/strong\u003e; Cash position of \u003cstrong\u003e$12.7 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Diversified Clinical Pipeline Breadth\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Evaluating Gemini across CKD, AKI, post-surgical infection prevention, and severe burn patients diversifies risk away from a single indication failure.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Gemini program targets multiple indications: GEMINI-AKI, GEMINI-PSI, GEMINI-CKD, and GEM-PBI.\u003c\/li\u003e\n\u003cli\u003eAcute Kidney Injury (AKI) affects more than \u003cstrong\u003e10%\u003c\/strong\u003e of all hospitalized patients and over \u003cstrong\u003e50%\u003c\/strong\u003e of patients in intensive care units.\u003c\/li\u003e\n\u003cli\u003eIn severe burn patients, invasive infection accounts for an estimated \u003cstrong\u003e51%\u003c\/strong\u003e of deaths.\u003c\/li\u003e\n\u003cli\u003eThe PRIME Phase 1b study in CKD enrolled \u003cstrong\u003e40\u003c\/strong\u003e participants across \u003cstrong\u003e3\u003c\/strong\u003e U.S.-based clinics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eProgram Code\u003c\/td\u003e\n\u003ctd\u003eTarget Population\/Context\u003c\/td\u003e\n\u003ctd\u003eAssociated Statistical Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute Kidney Injury\u003c\/td\u003e\n\u003ctd\u003eGEMINI-AKI\u003c\/td\u003e\n\u003ctd\u003eHospitalized\/ICU patients\u003c\/td\u003e\n\u003ctd\u003eAffects over \u003cstrong\u003e50%\u003c\/strong\u003e of ICU patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Surgical Infection Prevention\u003c\/td\u003e\n\u003ctd\u003eGEMINI-PSI\u003c\/td\u003e\n\u003ctd\u003ePost-surgical setting\u003c\/td\u003e\n\u003ctd\u003eImplied large market size based on other infection indications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Kidney Disease\u003c\/td\u003e\n\u003ctd\u003eGEMINI-CKD\u003c\/td\u003e\n\u003ctd\u003eStage 3 and 4 CKD patients\u003c\/td\u003e\n\u003ctd\u003ePRIME study enrolled \u003cstrong\u003e40\u003c\/strong\u003e patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere Burn Infection Prevention\u003c\/td\u003e\n\u003ctd\u003eGEM-PBI\u003c\/td\u003e\n\u003ctd\u003eSevere burn patients requiring hospitalization\u003c\/td\u003e\n\u003ctd\u003eInvasive infection is primary cause of death after 24 hours.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. Many biotechs focus on one indication initially; this breadth shows a wider potential market.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Temporary. Competitors can expand their own platforms, but it requires time and capital.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2025, Revelation had \u003cstrong\u003e$5.2 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/li\u003e\n\u003cli\u003eNet cash used for operating activities for the three months ended June 30, 2025, was \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company received gross proceeds of \u003cstrong\u003e$4 million\u003c\/strong\u003e from a public offering in May 2025.\u003c\/li\u003e\n\u003cli\u003eThe company believes current cash is sufficient to fund operations through \u003cstrong\u003eDecember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Good. They actively manage multiple programs, which requires coordination.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. The value is in the optionality, but execution risk is higher across more fronts.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss for the three months ended June 30, 2025, was \u003cstrong\u003e$2.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization as of November 20, 2025, was approximately \u003cstrong\u003e$5.06 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Access to Capital\/Financing Capability\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eAccess to Capital\/Financing Capability\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe ability to raise necessary funds to bridge operational gaps, demonstrated by securing $9.6 million in gross proceeds from warrant inducement in September 2025.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. In a tough market, securing capital when cash reserves are tight (only $5.2 million as of June 30, 2025) is a key skill.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow. This depends on investor confidence, market timing, and existing warrant structures, which are hard to copy exactly.\u003c\/p\u003e\n\u003cp\u003eSpecifics of the September 2025 transaction involved:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGross Proceeds: $9.6 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eShares purchased via warrant exercise: Up to 4,355,000 shares.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExercise Price: $2.20 per share.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNew Class I Warrants issued for up to 13,065,000 shares.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eStrong. CEO James Rolke clearly prioritizes financing to maintain operations through December 2025 and beyond.\u003c\/p\u003e\n\u003cp\u003eOrganizational execution in financing is evidenced by recent financial events:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q2 2025 Period End)\u003c\/th\u003e\n\u003cth\u003eValue (Sept 2025 Transaction)\u003c\/th\u003e\n\u003cth\u003eValue (Q1 2025 Period End)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.2 million\u003c\/strong\u003e (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.7 million\u003c\/strong\u003e (as of 3\/31\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds Raised\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.6 million\u003c\/strong\u003e (Warrant Inducement)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4 million\u003c\/strong\u003e (Public Offering in May 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (3 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used for Operating Activities (3 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eShareholder approval for the issuance related to Class I Warrants involved:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eShares present for quorum: 2,460,527.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal outstanding shares at the time: 5,924,137.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eVotes in favor of issuance: 2,347,650.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eVotes against issuance: 109,808.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. This advantage is only sustained as long as investors remain confident in the near-term data catalysts.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Management Team Expertise (CEO James Rolke)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Experienced leadership, like CEO James Rolke, is crucial for navigating clinical trials, regulatory submissions, and financing rounds.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many firms have CEOs, one with a proven track record in this specific therapeutic area is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Leadership experience and network effects are built over decades and are not easily replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The team is clearly driving toward specific milestones, like the FDA meeting and data announcements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Good leadership is a long-term, hard-to-replicate asset.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eArea of Expertise\u003c\/th\u003e\n\u003cth\u003eMetric\/Achievement\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Industry Experience\u003c\/td\u003e\n\u003ctd\u003eYears in Biotechnology\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e30\u003c\/strong\u003e years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Success\u003c\/td\u003e\n\u003ctd\u003eMarketing Approvals Overseen\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e (Giapreza, artesunate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Pipeline Advancement\u003c\/td\u003e\n\u003ctd\u003eInvestigational New Drugs (INDs) Oversaw\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Device Approvals\u003c\/td\u003e\n\u003ctd\u003ePMA\/510(k) Pathways Navigated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Tenure\u003c\/td\u003e\n\u003ctd\u003eCEO Since Inception\u003c\/td\u003e\n\u003ctd\u003eMay \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCEO James Rolke's tenure and achievements provide tangible evidence of organizational capability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRolke oversaw development resulting in marketing approvals for Giapreza (US FDA and EMEA) and artesunate.\u003c\/li\u003e\n\u003cli\u003ePrior role at Pluromed, Inc. involved key roles in approvals of \u003cstrong\u003e2\u003c\/strong\u003e medical devices via the \u003cstrong\u003e510(k)\u003c\/strong\u003e and \u003cstrong\u003ePMA\u003c\/strong\u003e pathways.\u003c\/li\u003e\n\u003cli\u003eRevelation Biosciences reported cash and cash equivalents of \u003cstrong\u003e$12.7 million\u003c\/strong\u003e as of September 30, \u003cstrong\u003e2025\u003c\/strong\u003e, up from \u003cstrong\u003e$6.5 million\u003c\/strong\u003e as of December 31, \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company secured gross proceeds of \u003cstrong\u003e$9.6 million\u003c\/strong\u003e from a September \u003cstrong\u003e2025\u003c\/strong\u003e warrant inducement.\u003c\/li\u003e\n\u003cli\u003eThe PRIME Phase 1b Clinical Study of Gemini in CKD Patients completed dosing.\u003c\/li\u003e\n\u003cli\u003eThe company is on track for an End-of-Phase 1 meeting with the FDA later in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, \u003cstrong\u003e2025\u003c\/strong\u003e, the company had \u003cstrong\u003e9\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended September 30, \u003cstrong\u003e2025\u003c\/strong\u003e was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: Collaboration with Academic\/Research Institutions\n\u003c\/h2\u003e\n\u003cp\u003eThe collaboration with Vanderbilt University and Dr. Julia Bohannon centers on developing Gemini (phosphorylated hexaacyl disaccharide, PHAD) for the prevention of infection in severe burn patients (GEM-PBI program), which is part of a patent family licensed from Vanderbilt.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used for Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.06 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 20, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued US Patent from License\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11,389,465\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExclusive worldwide license from Vanderbilt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe severe burn patient population presents significant unmet medical need:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe total annual number of burn-related deaths is approximately \u003cstrong\u003e3,400\u003c\/strong\u003e, with invasive infection being the primary cause of death after the first 24 hours.\u003c\/li\u003e\n\u003cli\u003eInvasive infection, including sepsis, accounts for an estimated \u003cstrong\u003e51%\u003c\/strong\u003e of deaths after burn injury.\u003c\/li\u003e\n\u003cli\u003eThe overall mortality rate for severe burn patients is about \u003cstrong\u003e3.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis mortality rate increases to \u003cstrong\u003e20.6%\u003c\/strong\u003e in burn patients with cutaneous burn and inhalation injury.\u003c\/li\u003e\n\u003cli\u003ePreclinical research showed treatment post-burn significantly reduces the severity and duration of \u003cem\u003epseudomonas\u003c\/em\u003e lung infection and reduces overall inflammation in a preclinical model.\u003c\/li\u003e\n\u003cli\u003eThe license agreement covers potential applications including prevention or reduction of acquired infections resulting from severe burns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003ePartnerships, such as the ongoing collaboration with Vanderbilt and Dr. Bohannon regarding severe burns, provide external validation and specialized expertise. The collaboration leverages preclinical data showing Gemini reduces infection severity and duration, correlating with observed clinical biomarker activity. The license grants use of issued US patent \u003cstrong\u003e11,389,465\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Many firms have academic ties, but specific, productive relationships in niche areas are valuable. The exclusive worldwide license agreement for PHAD to develop treatments for severe burns is a specific asset.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eTemporary. Competitors can seek out similar academic partners, but established relationships are sticky. The existing relationship and continued prosecution of additional patent applications provide a time-based advantage.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eGood. They are actively leveraging external resources to expand the pipeline, announcing the GEM-PBI program as a new target indication for Gemini. The company's cash position as of March 31, 2025, was \u003cstrong\u003e$3.7 million\u003c\/strong\u003e, against a market capitalization of \u003cstrong\u003e$5.06 million\u003c\/strong\u003e as of November 20, 2025, indicating resource constraints in funding extensive external research independently.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. It helps accelerate development but isn't a barrier to entry for well-funded rivals. The CEO noted the GEM-PBI program may offer several regulatory, development, and funding opportunities the company plans to explore.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRevelation Biosciences, Inc. (REVB) - VRIO Analysis: NASDAQ Listing Status\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eNASDAQ Listing Status\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eMaintaining a listing on NASDAQ provides public visibility, a liquid trading mechanism for shares, and easier access to public equity markets for future financing.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLow. Many clinical-stage biotechs are listed, but maintaining compliance (which required a \u003cstrong\u003e1-for-16\u003c\/strong\u003e reverse stock split in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e) is a baseline requirement.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh. Any competitor can list, but the current compliance is a resource in itself.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eNecessary. The organization must dedicate resources to SEC filings and corporate governance to keep this status.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone. This is a necessary cost of doing business for a public biotech, though failure to maintain it is a major risk.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003ctd\u003eDate\/Ratio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReverse Stock Split Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1-for-16\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 28, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurpose of Split\u003c\/td\u003e\n\u003ctd\u003eRegain compliance with minimum bid continued listing requirement\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCUSIP Change\u003c\/td\u003e\n\u003ctd\u003eNew CUSIP: \u003cstrong\u003e76135L606\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEffective \u003cstrong\u003eJanuary 28, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinancial Data Points\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and Cash Equivalents as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$5.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e: \u003cstrong\u003e$6.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Cash Used for Operating Activities (3 months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e): \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Proceeds from Public Offering: \u003cstrong\u003e$4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Proceeds from Warrant Inducement: \u003cstrong\u003e$9.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Equivalents as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$12.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Q4 2025 Cash Burn Projection and Runway Past December 2025\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProjected Q4 2025 Net Cash Used for Operating Activities (3-month basis, based on Q2 2025 rate): \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eLatest Stated Runway Past December 2025 (as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e cash position): Sufficient to fund operations through the \u003cstrong\u003ethird quarter of 2026\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516240650389,"sku":"revb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/revb-vrio-analysis.png?v=1740211073","url":"https:\/\/dcf-model.com\/products\/revb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}